GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Physiological Profile of Recovery From Resistance, Endurance, and Mixed Exercise Types

Not Applicable

Completed

Conditions: Sports Nutritional Sciences

Interventions: Other: High-Intensity stochastic cycling session
Other: Resistance exercise weight training session
Other: Simulated Team sport protocol

First Posted Date: 2017-03-20

Last Posted Date: 2017-08-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT03083509

Locations: 🇬🇧
GSK Investigational Site, Brentford, United Kingdom

First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: GSK3036656
Drug: Placebo

First Posted Date: 2017-03-09

Last Posted Date: 2019-04-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT03075410

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity

Phase 3

Completed

Conditions: Dentine Hypersensitivity

Interventions: Drug: Stannous Fluoride
Drug: Sodium Monofluorophosphate

First Posted Date: 2017-03-07

Last Posted Date: 2018-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT03072719

Locations: 🇮🇪
GSK Investigational Site, Cork, Ireland

Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging

Phase 1

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: GSK3008348
Drug: Placebo
Drug: [18F]-FBA-A20FMDV2

First Posted Date: 2017-03-03

Last Posted Date: 2019-08-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 8

Registration Number: NCT03069989

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Dermatitis, Atopic

Interventions: Drug: Mepolizumab 100 mg
Drug: Placebo matching mepolizumab

First Posted Date: 2017-02-16

Last Posted Date: 2020-02-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 34

Registration Number: NCT03055195

Locations: 🇨🇦
GSK Investigational Site, Quebec, Canada

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: GSK2838232
Drug: Cobicistat

First Posted Date: 2017-02-08

Last Posted Date: 2020-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 33

Registration Number: NCT03045861

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: In-person focus groups
Other: Telephone interviews
Other: DCE surveys- cognitive interviews
Other: Online DCE survey
Other: Modified DCE